Downregulation of Organ‐Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Cui Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Basic Medicine, School of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China. Hauptthemen laut MEDLINE: Cachexia, Muscular Atrophy, Adipose Tissue, Activins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Project, Guangdong Medical Science and Technology Research Foundation.
Abstract (Originalsprache)
Background
Cancer cachexia is a multifactorial wasting syndrome marked by profound skeletal muscle loss. Tumours can release high levels of Activin A (ActA), which activates the ubiquitin‐proteasome pathway (UPP) and drives muscle wasting. Systemic blockade of the ActA pathway is associated with inflammatory adverse effects, and tumour‐restricted targeting alone often fails to reverse cachexia. We asked whether ActA produced by host (nontumour) organs contributes to circulating ActA and muscle wasting.
Methods
We profiled ActA across tissues and in serum in Lewis lung carcinoma (LLC) cancer cachexia mice to generate an organ‐wide expression map. Functional studies were then performed using adeno‐associated‐virus (AAV)‐knockdown in the heart (cTnT/hTCF21 promoters) and kidney (CMV promoter), followed by cachexia induction. Body weight (BW), food intake, skeletal muscle mass, muscle function and muscle histomorphology were assessed. Mitochondrial ultrastructure and lipid metabolic pathways in muscle and adipose tissue were also examined.
Results
LLC cachexia mice exhibited significant reductions in body weight ( − 6.0%, p < 0.05), food intake (−9.9%, p < 0.05), quadriceps mass (−15.3%, p < 0.05) and grip strength (−13.0%, p < 0.0001) compared with non–tumour‐bearing (NTB) mice ( n = 6–12/group). ActA expression was markedly increased in the host organs, particularly in the kidney (2.8‐fold vs. NTB, p < 0.001) and heart (2.7‐fold vs. NTB, p < 0.05) ( n = 10/group). Compared with the sh‐NC, organ‐targeted ActA knockdown restored body weight (+6.1%, p < 0.05) and food intake (+8.4% , p < 0.05), increased quadriceps mass (+17.2%, p < 0.05) and grip strength (+10.7%, p < 0.01), reduced intramuscular fat infiltration and attenuated UPP signalling ( n = 8–16/group). These effects were accompanied by increased expression of the mitochondrial fatty‐acid oxidation regulator carnitine palmitoyltransferase 1B (CPT1B) (+42.3% of mRNA level; +30.9% of protein level; both p < 0.05) and CPT2 (+57.7% of mRNA level, p < 0.05), improved mitochondrial ultrastructure and partial restoration of adipose mass.
Conclusions
Simultaneous downregulation of Activin A in the kidney and heart attenuates skeletal muscle atrophy and intramuscular adipogenesis, improves muscle mass and function and mitigates adipose tissue mass loss in cancer cachexia mice. These findings identify heart‐ and kidney‐derived Activin A as a key driver of cachexia, which acts through a combinatorial effect rather than an isolated contribution from either one alone, highlighting its potential as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Basic Medicine, School of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
- Department of Medical Research Center, Yuebei People's Hospital Affiliated to Shantou University Medical College, Shaoguan, China.
- Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Key Laboratory of Genitourinary Tumor, Department of Urology, Shenzhen Institute of Translational Medicine, Th…
- Shenzhen Key Laboratory of Metabolic Health, Center for Energy Metabolism and Reproduction, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
- Department of Nephrology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
- Department of Critical Care Medicine, Longgang Central Hospital (Shenzhen Clinical College), Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
ORCID-Profile: Zesong Li
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Project
- Guangdong Medical Science and Technology Research Foundation
Zitieren
APA
Wang, C., Gao, L., Xue, R., Su, J., Li, H., Yang, W., Tang, Y., Su, Z., Min, S., Tang, C., Zhu, Y., Mu, B., Speakman, J. R., Xie, X., & Li, Z. (2026). Downregulation of Organ‐Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70237
Vancouver
Wang C, Gao L, Xue R, Su J, Li H, Yang W, et al. Downregulation of Organ‐Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70237
BibTeX
@article{Wang2026,
author = {Wang, Cui and Gao, Lin and Xue, Rui and Su, Jia and Li, Honghui and Yang, Wei and Tang, Yan and Su, Zhihang and Min, Shasha and Tang, Changyong and Zhu, Yuqi and Mu, Bo and Speakman, John R and Xie, Xina and Li, Zesong},
title = {Downregulation of Organ‐Derived Activin A Attenuates Muscle Atrophy and Intramuscular Fat Infiltration in Cancer Cachexia Mice},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70237}
}
EUVIMED